Leerink Partners analyst Joseph Schwartz maintained a Buy rating on Protagonist Therapeutics (NASDAQ:PTGX) on Tuesday, setting a price target of $41, which is approximately 40.51% above the present share price of $29.18.
Schwartz expects Protagonist Therapeutics to post earnings per share (EPS) of -$0.48 for the second quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Protagonist Therapeutics, with an average price target of $39.33.
The analysts price targets range from a high of $41 to a low of $36.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $5.65 million and a net profit of -$18.83 million. The company's market cap is $1.28 billion.
According to TipRanks.com, Leerink Partners analyst Joseph Schwartz is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 13.7% and a 46.48% success rate.
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. The firm's initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn's disease, respectively. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.